Inhibikase Therapeutics
IKT----
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Preview: Inhibikase Therapeutics(IKT) predict that the EBIT is -17.84 M (-22.22%), Miss estimate;the EPS is -0.1 (+33.33%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.02B22.22%
-0.02B4.73%
-0.00B17.49%
EPSExceed expectations
-0.133.33%
-0.1126.67%
+0.01006.66%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf